Brief: Fusion Pharmaceuticals And Bwxt Medical Announce Actinium-225 Partnership To Scale Supply For Developing Targeted Alpha Therapies
05/01/2023 22:24
Jan 5 (Reuters) - BWX Technologies Inc BWXT.N :
* FUSION PHARMACEUTICALS AND BWXT MEDICAL ANNOUNCE
ACTINIUM-225
PARTNERSHIP TO SCALE SUPPLY FOR DEVELOPING TARGETED ALPHA
THERAPIES
* FUSION PHARMACEUTICALS - UNDER AGREEMENT, BWXT MEDICAL
WILL
PROVIDE PREDETERMINED AMOUNTS OF FUSION'S ACTINIUM SUPPLY NEEDS
AT VOLUME-BASED PRICING
Source text for Eikon: ID:nCNWGtM5va
Further company coverage: BWXT.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary